Kymera Investor Presentation Deck

● ● ● Overall, KT-333 well tolerated with primarily Gr. 1-2 AEs 2 DLTs observed (Gr. 3 stomatitis, Gr. 3 arthralgia) both in LGL-L patients at DL5; No DLTs in solid tumor/lymphoma patients at any dose level ■ Led to protocol amendment to assess safety/MTD in solid tumor and lymphoma patients separately from leukemic patients (LGL-L, T-PLL) Solid tumor/lymphoma- currently at DL5 with plan to continue dose escalation as planned LGL-L/T-PLL- currently at DL3 with max escalation to DL4 Most common related AEs across all patients (n=29), n (%): Stomatitis, 6 (21%) ALT increase, 3 (10%)* AST increase, 2 (7%)* Related Grade 3 AEs**: 1 pt each: Stomatitis, arthralgia, weight decreased ● ● ● ● KT-333 Safety Summary *all Gr 1; **no Gr 4 or Gr 5 related AEs KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 28

View entire presentation